Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions, particularly in the field of oncology, and Mepha Pharma AG (Mepha) signed an exclusive distribution agreement in Switzerland for the 1, 3 and 6 month formulations of Pamorelin LA.
The product, which contains the active substance triptorelin pamoate, is indicated for the treatment of prostate cancer, endometriosis and female infertility. Developed by Debiopharm, Pamorelin LA is being manufactured at Debio R P in Martigny, the company's research, development and production facility inspected by Swissmedic and the United States (US) Food and Drug Administration (FDA).
Andreas Bosshard, CEO of Mepha, Rolland-Yves Mauvernay, president and founder of Debiopharm Group and Bertrand Ducrey, CEO of Debio R P met in Martigny on the May 8 for a high-level kick-off meeting. The launch of Pamorelin LA in Switzerland is expected in mid-2009.
"We are pleased that Mepha has recognised the added value and comfort that Pamorelin LA will provide for prostate cancer patients in Switzerland," said Rolland-Yves Mauvernay. "We look forward to launching our product with an experienced Swiss company like Mepha, who has proven expertise in the commercialisation of high quality products."
"We are happy to be working alongside an innovative drug developer like Debiopharm for the distribution of Pamorelin LA in Switzerland. This is concurrent to our existing innovative drug-line," added Andreas Bosshard.
Triptorelin, a luteinizing hormone releasing hormone (LHRH) agonist, was licensed-in from Tulane University, in 1982.
Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biological and small molecule drug candidates.
Mepha is the leading company in the Swiss generic market and is strongly present in all distribution channels (pharmacists, medical doctors, hospitals). Mepha develops and produces attractive medical products and services in Switzerland to enable doctors and pharmacists to treat their patients with high effectiveness and cost awareness.